$0.43
-0.01 (-2.00%)
Open$0.44
Previous Close$0.44
Day High$0.45
Day Low$0.42
52W High$2.30
52W Low$0.38
Volume—
Avg Volume3.92M
Market Cap77.60M
P/E Ratio—
EPS$-0.18
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+5,244.4% upside
Current
$0.43
$0.43
Target
$22.81
$22.81
$15.42
$22.81 avg
$25.92
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 172.72M | 153.01M | 36.22M |
| Net Income | -22,509,965 | -17,947,349 | -2,507,722 |
| Profit Margin | -13.0% | -12.4% | -6.9% |
| EBITDA | -12,900,013 | -10,856,672 | -3,086,652 |
| Free Cash Flow | — | — | -2,753,402 |
| Rev Growth | +12.9% | +12.9% | +20.2% |
| Debt/Equity | 9.81 | 9.81 | 0.74 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |